Dunn Philip M, Kim Hak Sung, Jacobson Kenneth A, Burnstock Geoffrey
Autonomic Neuroscience Institute, Royal Free and University College Medical School, London, United Kingdom.
Drug Dev Res. 2004 Apr;61(4):227-232. doi: 10.1002/ddr.10381. Epub 2004 Sep 22.
Strategy, Management and Health PolicyEnabling Technology, Genomics, ProteomicsPreclinical ResearchPreclinical Development Toxicology, Formulation Drug Delivery, PharmacokineticsClinical Development Phases I-III Regulatory, Quality, ManufacturingPostmarketing Phase IVReplacement of the ribose moiety of adenosine 5'-triphosphate (ATP) with a carbocyclic ring constrained in either the Northern (N) or Southern (S) conformation produces agonists with widely differing activities at P2Y receptors (Kim et al. [2002] J Med Chem 45:208-218). We have used whole cell patch clamp recording to investigate the agonist activity of these two methanocarba analogs of ATP at four different P2X receptors (P2X(1), P2X(2), P2X(3), and P2X(2/3)). On dorsal root ganglion neurons, (N) methanocarba-ATP ((1'S,2'R,3'S,4'R,5'S)-4-(6-amino-9H-purin-9-yl)-1-[triphosphoryloxymethyl] bicyclo[ 3.1.0]hexane-2,3-diol; MRS 2340) activated rapidly-desensitizing (P2X(3)) and slowly-desensitizing (P2X(2/3)) receptors with a similar potency to ATP. In contrast, (S) methanocarba-ATP ((±)-5-(6-amino-9H-purin-9-yl)-1-[triphosphoryloxymethyl] bicycle [3.1.0]hexane-2,3-diol MRS 2312) was devoid of agonist activity. On nodose ganglion neurones, that express mainly P2X(2/3) receptors, ATP evoked a slowly desensitizing inward current with an EC(50) value of 26 μM. MRS 2340 was an effective agonist, but less potent than ATP, while MRS 2312 at concentrations up to 100 μM produced a barely detectable response. On mammalian cell lines expressing recombinant hP2X(1) and hP2X(2) receptors, MRS 2340 evoked inward currents similar in amplitude to those produced by the same concentration of ATP or α,β-mATP. In contrast, MRS 2312 failed to give a detectable response. Although the conformation of the ribose affects agonist activity at P2Y receptors, there is a strong requirement for the (N) conformation for the activation of these P2X receptors. Furthermore, the region of the agonist binding site that accommodates the ribose moiety appears to be highly conserved among different P2X receptors. Drug Dev Res 61:227-232, 2004.
策略、管理与卫生政策
使能技术、基因组学、蛋白质组学
临床前研究
临床前开发 毒理学、制剂 药物递送、药代动力学
临床开发 Ⅰ - Ⅲ期 监管、质量、生产
上市后 Ⅳ期
用一个在北(N)或南(S)构象中受约束的碳环取代腺苷5'-三磷酸(ATP)的核糖部分,可产生在P2Y受体上具有广泛不同活性的激动剂(Kim等人[2002]《药物化学杂志》45:208 - 218)。我们已使用全细胞膜片钳记录来研究这两种ATP的甲碳环类似物在四种不同P2X受体(P2X(1)、P2X(2)、P2X(3)和P2X(2/3))上的激动剂活性。在背根神经节神经元上,(N)甲碳环 - ATP((1'S,2'R,3'S,4'R,5'S)-4-(6 - 氨基 - 9H - 嘌呤 - 9 - 基)-1 - [三磷酸化氧甲基]双环[3.1.0]己烷 - 2,3 - 二醇;MRS 2340)激活快速脱敏(P2X(3))和缓慢脱敏(P2X(2/3))受体,其效力与ATP相似。相比之下,(S)甲碳环 - ATP((±)-5-(6 - 氨基 - 9H - 嘌呤 - 9 - 基)-1 - [三磷酸化氧甲基]双环[3.1.0]己烷 - 2,3 - 二醇 MRS 2312)没有激动剂活性。在主要表达P2X(2/3)受体的结状神经节神经元上,ATP诱发缓慢脱敏的内向电流,EC(50)值为26 μM。MRS 2340是一种有效的激动剂,但效力低于ATP,而浓度高达100 μM的MRS 2312产生的反应几乎无法检测到。在表达重组hP2X(1)和hP2X(2)受体的哺乳动物细胞系上,MRS 2340诱发的内向电流幅度与相同浓度的ATP或α,β - mATP产生的电流相似。相比之下,MRS 2312未能产生可检测到的反应。尽管核糖的构象影响P2Y受体上的激动剂活性,但激活这些P2X受体强烈需要(N)构象。此外,容纳核糖部分的激动剂结合位点区域在不同的P2X受体之间似乎高度保守。《药物研发研究》61:227 - 232,2004年。